Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

NCT04094051 · clinicaltrials.gov ↗

UNKNOWN

Status

580

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Ibrutinib

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Collaborators

[object Object]